Literature DB >> 24100137

Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).

Liping Zhang1, Hong Zhang, Yining Zhao, Zhe Li, Shangke Chen, Jing Zhai, Yunyun Chen, Wei Xie, Zhong Wang, Qing Li, Xuehua Zheng, Xiaopeng Hu.   

Abstract

The antineoplastic target aldo-keto reductase family member 1B10 (AKR1B10) and the critical polyol pathway enzyme aldose reductase (AKR1B1) share high structural similarity. Crystal structures reported here reveal a surprising Trp112 native conformation stabilized by a specific Gln114-centered hydrogen bond network in the AKR1B10 holoenzyme, and suggest that AKR1B1 inhibitors could retain their binding affinities toward AKR1B10 by inducing Trp112 flip to result in an "AKR1B1-like" active site in AKR1B10, while selective AKR1B10 inhibitors can take advantage of the broader active site of AKR1B10 provided by the native Trp112 side-chain orientation.
Copyright © 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AKR1A1; AKR1B1; AKR1B10; Crystal structure; FLF; Inhibitor selectivity; aldehyde reductase; aldose reductase aldo–keto reductase family1 member1; aldo–keto reductase family1 member10; flufenamic acid

Mesh:

Substances:

Year:  2013        PMID: 24100137     DOI: 10.1016/j.febslet.2013.09.031

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  14 in total

1.  Dietary flavonoids inhibit the glycation of lens proteins: implications in the management of diabetic cataract.

Authors:  Rohan J Meshram; Kapil K Patil; Sagar H Barage; Rajesh N Gacche
Journal:  3 Biotech       Date:  2019-01-23       Impact factor: 2.406

2.  Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases.

Authors:  Dustyn A Barnette; Bryce P Johnson; Dakota L Pouncey; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2017-06-23       Impact factor: 3.922

3.  Synthesis and characterization of novel acyl hydrazones derived from vanillin as potential aldose reductase inhibitors.

Authors:  Yeliz Demir; Feyzi Sinan Tokalı; Erbay Kalay; Cüneyt Türkeş; Pelin Tokalı; Osman Nuri Aslan; Kıvılcım Şendil; Şükrü Beydemir
Journal:  Mol Divers       Date:  2022-09-14       Impact factor: 3.364

4.  Novel chemical scaffolds of the tumor marker AKR1B10 inhibitors discovered by 3D QSAR pharmacophore modeling.

Authors:  Raj Kumar; Minky Son; Rohit Bavi; Yuno Lee; Chanin Park; Venkatesh Arulalapperumal; Guang Ping Cao; Hyong-ha Kim; Jung-keun Suh; Yong-seong Kim; Yong Jung Kwon; Keun Woo Lee
Journal:  Acta Pharmacol Sin       Date:  2015-06-08       Impact factor: 6.150

5.  Characterization of Emodin as a Therapeutic Agent for Diabetic Cataract.

Authors:  Kun-Che Chang; Linfeng Li; Theresa M Sanborn; Biehuoy Shieh; Patricia Lenhart; David Ammar; Daniel V LaBarbera; J Mark Petrash
Journal:  J Nat Prod       Date:  2016-05-03       Impact factor: 4.050

Review 6.  Aldo Keto Reductases AKR1B1 and AKR1B10 in Cancer: Molecular Mechanisms and Signaling Networks.

Authors:  Sreeparna Banerjee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  2D-DIGE proteomic analysis identifies new potential therapeutic targets for adrenocortical carcinoma.

Authors:  Giada Poli; Elisabetta Ceni; Roberta Armignacco; Tonino Ercolino; Letizia Canu; Gianna Baroni; Gabriella Nesi; Andrea Galli; Massimo Mannelli; Michaela Luconi
Journal:  Oncotarget       Date:  2015-03-20

8.  Selective Inhibition of Human AKR1B10 by n-Humulone, Adhumulone and Cohumulone Isolated from Humulus lupulus Extract.

Authors:  Jan Moritz Seliger; Serhat Sezai Cicek; Lydia T Witt; Hans-Jörg Martin; Edmund Maser; Jan Hintzpeter
Journal:  Molecules       Date:  2018-11-21       Impact factor: 4.411

9.  Substrate Specificity, Inhibitor Selectivity and Structure-Function Relationships of Aldo-Keto Reductase 1B15: A Novel Human Retinaldehyde Reductase.

Authors:  Joan Giménez-Dejoz; Michal H Kolář; Francesc X Ruiz; Isidro Crespo; Alexandra Cousido-Siah; Alberto Podjarny; Oleg A Barski; Jindřich Fanfrlík; Xavier Parés; Jaume Farrés; Sergio Porté
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 10.  Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.

Authors:  Li Huang; Rongzhang He; Weihao Luo; Yuan-Shan Zhu; Jia Li; Tan Tan; Xi Zhang; Zheng Hu; Dixian Luo
Journal:  Recent Pat Anticancer Drug Discov       Date:  2016       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.